Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Non-small Cell Lung Cancer Patients
100%
Immune Checkpoint Blockade
100%
Overall Survival
100%
Body Mass Index
100%
Non-linear Association
100%
Immune Checkpoint Inhibitors
33%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
33%
Objective Response Rate
22%
Progression-free Survival
22%
Survival Response
22%
Histology
11%
Locally Advanced
11%
Adenocarcinoma
11%
Multivariable
11%
Mortality Risk
11%
Retrospective Analysis
11%
Single Institution
11%
Survival Analysis
11%
Cox Regression
11%
Risk of Death
11%
Survival Outcomes
11%
Median Body
11%
Never-smokers
11%
Restricted Cubic Spline
11%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Body Mass Index
100%
Overall Survival
100%
Immune Checkpoint Blockade
100%
Oncology
33%
Immune Checkpoint Inhibitor
33%
Progression Free Survival
22%
Adenocarcinoma
11%
Survival Analysis
11%
Proportional Hazards Model
11%
Electrocorticography
11%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Overall Survival
100%
Body Mass
100%
Progression Free Survival
22%
Electrocorticography
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Overall Survival
100%
Immune Checkpoint Inhibitor
60%
Progression Free Survival
40%
Adenocarcinoma
20%
Agricultural and Biological Sciences
Body Mass Index
100%
Lung
100%
Electrocorticography
11%